Targeted manipulation of m6A RNA modification through CRISPR-Cas-based strategies

被引:15
|
作者
Sun, Xiang [1 ,2 ]
Wang, Dan Ohtan [3 ,4 ,5 ]
Wang, Jinkai [1 ,2 ,6 ]
机构
[1] Sun Yat Sen Univ, Zhongshan Sch Med, Dept Med Informat, Guangzhou 510080, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Ctr Stem Cell Biol & Tissue Engn, Key Lab Stem Cells & Tissue Engn, Minist Educ, Guangzhou 510080, Guangdong, Peoples R China
[3] RIKEN, Ctr Biosyst Dynam Res, Chuo Ku, 2-2-3 Minatojima Minamimachi, Kobe, Hyogo 6500047, Japan
[4] Kyoto Univ, Grad Sch Biostudies, Yoshida Hon Machi, Kyoto 6068501, Japan
[5] Shenyang Pharmaceut Univ, Wuya Coll Innovat, Shenyang 110016, Liaoning, Peoples R China
[6] Sun Yat Sen Univ, RNA Biomed Inst, Sun Yat Sen Mem Hosp, Guangzhou 510080, Guangdong, Peoples R China
基金
中国国家自然科学基金;
关键词
N-6-methyladenosine; CRISPR-Cas13; CRISPR-Cas9; Targeted manipulation; N-6-METHYLADENOSINE; RECOGNITION;
D O I
10.1016/j.ymeth.2022.03.006
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
N-6-methyladenosine (m(6)A) is a reversible and prevalent internal modification in RNAs and can be dynamically modulated by methyltransferase and demethylase. Targeted manipulation of m(6)A RNA modification is critical in studying the functions of specific m(6)A sites as well as developing molecular therapies through targeting m(6)A. The CRISPR-Cas systems including CRISPR-Cas9 and CRISPR-Cas13 have been widely used to edit and modify specific nucleotides on DNA and RNA through fusing effective proteins such as enzymes with Cas9/13. Through taking advantage of the m(6)A methyltransferase and demethylase, a series of CRISPR-Cas-based methods have also been developed to manipulate the m(6)A methylation at specific RNA sites. This review summarizes the latest CRISPR-Cas13 and Cas9 toolkits for m(6)A site-specific manipulation, including fundamental components, on-target efficiency, editing window, PAM/PFS requirement, and subcellularly localized targeting as well as potential limitations. We thus aim to provide an overview to assist researchers to choose an optimal tool to manipulate m(6)A for different purposes and also point out possible optimization strategies.
引用
收藏
页码:56 / 61
页数:6
相关论文
共 50 条
  • [41] A versatile toolkit for CRISPR-Cas13-based RNA manipulation in Drosophila
    Nhan Huynh
    Noah Depner
    Raegan Larson
    Kirst King-Jones
    Genome Biology, 21
  • [42] N6-methyladenosine (m6A) RNA modification in tumor immunity
    Zheng, Siyi
    Han, Hui
    Lin, Shuibin
    CANCER BIOLOGY & MEDICINE, 2022, 19 (04) : 385 - 397
  • [43] N6-methyladenosine(m6A) RNA modification in tumor immunity
    Siyi Zheng
    Hui Han
    Shuibin Lin
    Cancer Biology & Medicine, 2022, (04) : 385 - 397
  • [44] N6-methyladenosine (m6A) RNA modification in human cancer
    Huo, Fu-Chun
    Zhu, Zhi-Man
    Pei, Dong-Sheng
    CELL PROLIFERATION, 2020, 53 (11)
  • [45] Novel insights into m6A modification in circular RNA and implications for immunity
    Paramasivam, Arumugam
    Priyadharsini, Jayaseelan Vijayashree
    CELLULAR & MOLECULAR IMMUNOLOGY, 2020, 17 (06) : 668 - 669
  • [46] Biological roles of the RNA m6A modification and its implications in cancer
    Juyeong Hong
    Kexin Xu
    Ji Hoon Lee
    Experimental & Molecular Medicine, 2022, 54 : 1822 - 1832
  • [47] Quantitative analysis of m6A RNA modification by LC-MS
    Mathur, Lavina
    Jung, Sunhee
    Jang, Cholsoon
    Lee, Gina
    STAR PROTOCOLS, 2021, 2 (03):
  • [48] Nascent RNA m6A modification at the heart of the gene–retrotransposon conflict
    Victor Billon
    Gael Cristofari
    Cell Research, 2021, 31 : 829 - 831
  • [49] RNA m6A modification governs early human cardiomyocyte commitment
    Spano, Giulia
    Hegenbarth, Jana-Charlotte
    De Majo, Federica
    Tiburcy, Malte
    Zimmermann, Wolfram-Hubertus
    de Windt, Leon
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2022, 173 : S108 - S109
  • [50] Emerging roles of m6A RNA modification in cancer therapeutic resistance
    Wei-Wei Liu
    Zhong-Yuan Zhang
    Fei Wang
    Hao Wang
    Experimental Hematology & Oncology, 12